| abstract |
Compounds of the formula (I) provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) m ay be employed for prevention and treatment of impaired glucose tolerance, Type 2 diabetes and obesity, wherein Q is formula (II) or formula (III), R is a radical of the formula (IV) or (V) or (VI) wherein Y, R1-R6, R12 and R13 are as defined in the description. |